Achillion Pharmaceuticals (ACHN) Downgraded by BidaskClub to “Strong Sell”

BidaskClub downgraded shares of Achillion Pharmaceuticals (NASDAQ:ACHN) from a sell rating to a strong sell rating in a research report report published on Saturday morning.

ACHN has been the subject of several other research reports. Zacks Investment Research raised shares of Achillion Pharmaceuticals from a hold rating to a buy rating and set a $4.50 target price for the company in a research report on Monday, November 6th. Chardan Capital reaffirmed a neutral rating on shares of Achillion Pharmaceuticals in a report on Sunday, September 17th. Finally, Leerink Swann reaffirmed a buy rating and issued a $5.00 price target on shares of Achillion Pharmaceuticals in a report on Monday, December 11th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of $5.13.

Achillion Pharmaceuticals (NASDAQ ACHN) remained flat at $$2.99 on Friday. The stock had a trading volume of 1,467,546 shares, compared to its average volume of 2,774,815. The company has a market cap of $412.20, a P/E ratio of -6.23 and a beta of 1.53. Achillion Pharmaceuticals has a one year low of $2.69 and a one year high of $5.66.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.04. During the same quarter in the prior year, the company posted ($0.15) earnings per share. analysts forecast that Achillion Pharmaceuticals will post -0.63 EPS for the current year.

In other news, major shareholder & Johnson Johnson sold 18,367,346 shares of Achillion Pharmaceuticals stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $2.75, for a total value of $50,510,201.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 7.24% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the business. RTW Investments LP boosted its stake in Achillion Pharmaceuticals by 392.9% during the 3rd quarter. RTW Investments LP now owns 7,839,766 shares of the biopharmaceutical company’s stock valued at $35,201,000 after purchasing an additional 6,249,312 shares during the period. Janus Henderson Group PLC acquired a new position in Achillion Pharmaceuticals during the 2nd quarter valued at about $20,778,000. Dimensional Fund Advisors LP boosted its stake in Achillion Pharmaceuticals by 75.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 3,276,076 shares of the biopharmaceutical company’s stock valued at $14,710,000 after purchasing an additional 1,407,108 shares during the period. Sarissa Capital Management LP acquired a new position in Achillion Pharmaceuticals during the 3rd quarter valued at about $9,594,000. Finally, FMR LLC boosted its stake in Achillion Pharmaceuticals by 11.0% during the 2nd quarter. FMR LLC now owns 1,603,622 shares of the biopharmaceutical company’s stock valued at $7,361,000 after purchasing an additional 159,218 shares during the period. 76.92% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was posted by Week Herald and is the property of of Week Herald. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://weekherald.com/2018/01/14/achillion-pharmaceuticals-achn-downgraded-by-bidaskclub-to-strong-sell.html.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Analyst Recommendations for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply